Modified immune cell therapy for progressive multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old and weigh at least 88 pounds (40 kg).
- You have progressive multiple sclerosis (MS), not the relapsing-remitting type.
- You have tried at least one strong MS medication for 6 months or more, and it didn't control your MS.
- Your disability has clearly gotten worse over the last 2 years.
- Your walking ability is at a level where you can walk without help or need a cane or walker sometimes (EDSS 3.0–6.5).
- You have not had CAR T-cell therapy or gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new way to treat primary progressive multiple sclerosis (PPMS) using a stem cell transplant from a healthy donor. The goal is to see if this approach can stop or slow the disease and improve quality of life.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.